Skip to main navigation
Loading
  • News
  • Investors
  • Careers
  • Contact
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home
  • Menu Menu

SEC Filings

  • Overview
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Press Releases
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • IRS – Required Disclosures
  • SEC Filings
    • Quarterly Results
  • Contact
  • Email Alerts
Filing date Form Description Filing Group View
09-29-2023 S-4

Registration of securities issued in business combination transactions

Registration Statements
0001193125-23-246075.rtf
0001193125-23-246075.xls
0001193125-23-246075.pdf
View HTML
09-06-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-025312.rtf
0001437749-23-025312.xls
0001437749-23-025312.pdf
View HTML
09-06-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-025313.rtf
0001437749-23-025313.xls
0001437749-23-025313.pdf
View HTML
09-06-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-025318.rtf
0001437749-23-025318.xls
0001437749-23-025318.pdf
View HTML
09-06-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-025317.rtf
0001437749-23-025317.xls
0001437749-23-025317.pdf
View HTML
08-31-2023 8-K

Report of unscheduled material events or corporate event

Current Reports
0001193125-23-225486.rtf
0001193125-23-225486.xls
0001193125-23-225486.pdf
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
08-31-2023 425

Filing of certain prospectuses and communications in connection with business combination transactions

Other
0001193125-23-225488.rtf
0001193125-23-225488.xls
0001193125-23-225488.pdf
View HTML
08-31-2023 8-K

Report of unscheduled material events or corporate event

Current Reports
0001437749-23-024969.rtf
0001437749-23-024969.xls
0001437749-23-024969.pdf
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
08-31-2023 DEFA14A

Additional proxy soliciting materials - definitive

Proxy Filings
0001437749-23-024971.rtf
0001437749-23-024971.xls
0001437749-23-024971.pdf
View HTML
08-25-2023 4

Statement of changes in beneficial ownership of securities

3,4,5
0001437749-23-024680.rtf
0001437749-23-024680.xls
0001437749-23-024680.pdf
View HTML
Pagination
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »

Data provided by Kaleidoscope.

  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home

© 2023 Zevra Therapeutics, Inc. All rights reserved. Privacy Policy | Terms of Use

Scroll to top